Overview

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
Phase:
N/A
Details
Lead Sponsor:
Dr. Muhammad Abdulghani
Treatments:
Exenatide
Glucagon-Like Peptide 1
Insulin
Insulin Aspart
Insulin Glargine
Insulin, Globin Zinc
Pioglitazone